Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Jaguar Health Inc (JAGX)

Jaguar Health Inc (JAGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,221
  • Shares Outstanding, K 77,055
  • Annual Sales, $ 4,340 K
  • Annual Income, $ -52,610 K
  • 60-Month Beta 1.82
  • Price/Sales 6.94
  • Price/Cash Flow N/A
  • Price/Book 3.84
Trade JAGX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.28
  • Most Recent Earnings -0.40 on 05/10/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 412.01% ( +412.01%)
  • Historical Volatility 71.48%
  • IV Percentile 86%
  • IV Rank 35.93%
  • IV High 1,012.77% on 03/04/22
  • IV Low 75.08% on 05/10/22
  • Put/Call Vol Ratio 0.50
  • Today's Volume 15
  • Volume Avg (30-Day) 79
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 14,820
  • Open Int (30-Day) 14,339

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +333,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3600 +8.94%
on 05/11/22
0.5766 -31.98%
on 04/20/22
-0.1762 (-31.00%)
since 04/19/22
3-Month
0.3430 +14.34%
on 03/08/22
0.8150 -51.88%
on 03/31/22
-0.1553 (-28.37%)
since 02/18/22
52-Week
0.3430 +14.34%
on 03/08/22
6.8400 -94.27%
on 06/09/21
-3.1778 (-89.01%)
since 05/19/21

Most Recent Stories

More News
Media Advisory: Jaguar Health Canine Cancer: Take C.H.A.R.G.E. Launch Event in NYC on Monday, May 23rd!

Click here to RSVP for this in-person, outdoor event

JAGX : 0.3922 (+0.38%)
Media Advisory: Jaguar Health Canine Cancer: Take C.H.A.R.G.E. Launch Event in NYC on Monday, May 23rd!

Click Here To RSVP for This In-Person, Outdoor Event Human and Doggy Swag Will Be Available*, and the Event Will Feature Presentations by Well-Known Veterinary Cancer Specialists, Including Dr. Sue Cancer...

JAGX : 0.3922 (+0.38%)
TAG Investment Bankers Ltd. Issues Analyst Report on Jaguar Health

SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that TAG Investment Bankers Ltd. ("TAG") issued an analyst report today on the company. The paid report...

JAGX : 0.3922 (+0.38%)
Jaguar Health Announces Launch of Mytesi Telehealth Program

This Innovative Program Connects Patients Who May Be Suffering From HIV-Related Diarrhea to a Medical Provider Any Day of the Week and Almost Any Hour of the Day To Determine if Mytesi® Is Medically Appropriate...

JAGX : 0.3922 (+0.38%)
Jaguar Health Provides Company Updates and Reports 2022 First Quarter Financials

Mytesi® net revenue of $2.6 million increased approximately 24% over the fourth quarter of 2021 and increased approximately 112% over Mytesi net revenue in the first quarter of 2021 Core initiatives:...

JAGX : 0.3922 (+0.38%)
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, CA / ACCESSWIRE / May 6, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective May 6, 2022, the Company granted 50,000 restricted stock units...

JAGX : 0.3922 (+0.38%)
UPDATED RELEASE: Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

JAGX : 0.3922 (+0.38%)
Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

JAGX : 0.3922 (+0.38%)
Jaguar Health Completes Final Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea (EID) in Dogs

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

JAGX : 0.3922 (+0.38%)
Jaguar Animal Health Announces Commercial Availability of Plant-based Canalevia-CA1 (Crofelemer) Prescription Drug for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from FDA SAN FRANCISCO, CA / ACCESSWIRE / April 27, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar...

JAGX : 0.3922 (+0.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Jaguar Health, Inc. is a natural-products pharmaceuticals company. It focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals. The company through its subsidiary Napo Pharmaceuticals Inc., focuses on developing and commercializing...

See More

Key Turning Points

3rd Resistance Point 0.4267
2nd Resistance Point 0.4183
1st Resistance Point 0.4053
Last Price 0.3922
1st Support Level 0.3839
2nd Support Level 0.3755
3rd Support Level 0.3625

See More

52-Week High 6.8400
Fibonacci 61.8% 4.3581
Fibonacci 50% 3.5915
Fibonacci 38.2% 2.8249
Last Price 0.3922
52-Week Low 0.3430

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar